Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in Patients With Relapsed/Refractory Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-RRex)

NCT06514794 is registered in ClinicalTrials.gov with Allotera Therapeutics as lead sponsor.

NCT NCT06514794
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06514794 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in Patients With Relapsed/Refractory Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-RRex)
Lead sponsor
Allotera Therapeutics
Phase
Phase 2
Overall status
Recruiting
Start date
January 31, 2025
Completion date
December 30, 2028
Enrollment
125 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoblastic lymphoma, t-cell acute lymphoblastic leukemia